Neomycin should not be used to treat hepatic encephalopathy [7]

British Medical Journal

Volumn 323, Issue 7306, 2001, Pages 233-

  Curioso, W H ^a   Monkemuller, K E ^a  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LACTULOSE; METRONIDAZOLE; NEOMYCIN; PAROMOMYCIN; RIFAXIMIN;

DRUG EFFECT; DRUG INDICATION; DRUG TOLERABILITY; HEPATIC ENCEPHALOPATHY; HUMAN; LETTER; PRIORITY JOURNAL; SIDE EFFECT;

ANTI-BACTERIAL AGENTS; HEPATIC ENCEPHALOPATHY; HUMANS; NEOMYCIN; TREATMENT FAILURE;

EID: 0035963986     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. ABC of diseases of liver, pancreas, and biliary system: Portal hypertension-2. Ascites, encephalopathy, and other conditions
2. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy
3. Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial
4. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: A double-blind, randomized, dose-finding multi-centre study
5. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial